{
  "id": "mskcc_motzer_score",
  "title": "Memorial Sloan-Kettering Cancer Center (MSKCC/Motzer) Score for Metastatic Renal Cell Carcinoma (RCC)",
  "description": "Predicts survival based on clinical and laboratory data in metastatic RCC patients",
  "category": "oncology",
  "version": "1999",
  "parameters": [
    {
      "name": "time_to_treatment_less_than_1_year",
      "type": "string",
      "required": true,
      "description": "Time from initial diagnosis to systemic treatment < 1 year",
      "options": ["yes", "no"],
      "validation": {
        "enum": ["yes", "no"]
      }
    },
    {
      "name": "hemoglobin_low",
      "type": "string",
      "required": true,
      "description": "Hemoglobin < lower limit of normal (Men: <13.5 g/dL, Women: <12.0 g/dL)",
      "options": ["yes", "no"],
      "validation": {
        "enum": ["yes", "no"]
      }
    },
    {
      "name": "calcium_high",
      "type": "string",
      "required": true,
      "description": "Corrected calcium > 10 mg/dL (>2.5 mmol/L)",
      "options": ["yes", "no"],
      "validation": {
        "enum": ["yes", "no"]
      }
    },
    {
      "name": "ldh_high",
      "type": "string",
      "required": true,
      "description": "LDH > 1.5x upper limit of normal (Normal ULN: 140 U/L, so >210 U/L)",
      "options": ["yes", "no"],
      "validation": {
        "enum": ["yes", "no"]
      }
    },
    {
      "name": "performance_status_low",
      "type": "string",
      "required": true,
      "description": "Karnofsky Performance Status < 80%",
      "options": ["yes", "no"],
      "validation": {
        "enum": ["yes", "no"]
      }
    }
  ],
  "result": {
    "name": "mskcc_score",
    "type": "integer",
    "unit": "risk factors",
    "description": "Number of risk factors present"
  },
  "interpretation": {
    "ranges": [
      {
        "min": 0,
        "max": 0,
        "stage": "Good Risk",
        "description": "0 risk factors",
        "interpretation": "Good risk group with median survival of 20 months. These patients have the best prognosis and may be candidates for a variety of treatment approaches including targeted therapy, immunotherapy, or clinical trials."
      },
      {
        "min": 1,
        "max": 2,
        "stage": "Intermediate Risk",
        "description": "1-2 risk factors",
        "interpretation": "Intermediate risk group with median survival of 10 months. These patients require active treatment with targeted therapy or immunotherapy. Close monitoring is essential."
      },
      {
        "min": 3,
        "max": 5,
        "stage": "High Risk",
        "description": "≥3 risk factors",
        "interpretation": "High risk group with median survival of 4 months. These patients have poor prognosis and may benefit from aggressive systemic therapy, clinical trial enrollment, or supportive care depending on overall condition."
      }
    ]
  },
  "references": [
    "Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999 Aug;17(8):2530-40. doi: 10.1200/JCO.1999.17.8.2530.",
    "Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002 Jan 1;20(1):289-96. doi: 10.1200/JCO.2002.20.1.289.",
    "Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004 Feb 1;22(3):454-63. doi: 10.1200/JCO.2004.06.132."
  ],
  "formula": "Score = Sum of present risk factors (0-5)",
  "notes": [
    "Use baseline factors at the start of systemic therapy",
    "Always correct calcium concentration for low albumin using formula: Corrected Ca = Measured Ca + 0.8 × (4 - Albumin)",
    "Originally developed for patients treated with interferon-alpha",
    "The IMDC Risk Model is now preferred for patients receiving targeted therapy",
    "Karnofsky Performance Status < 80% indicates inability to carry out normal activities"
  ]
}